Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC)
    Meeting Abstract

    Lowery, M. A.; Kelsen, D. P.; Smith, S. C.; Moore, M.; Kindler, H. L.; Golan, T.; Segal, A.; Hollywood, E.; Maynard, H.; Capanu, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Trastuzumab interruption for treatment-induced cardiotoxicity in HER2 positive early breast cancer
    Meeting Abstract

    Yu, A. F.; Yadav, N. U.; Lung, B. Y.; Eaton, A. A.; Thaler, H. T.; Hudis, C. A.; Dang, C. T.; Steingart, R. M.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)
    Meeting Abstract

    Turner, N. C.; Balmana, J.; Domchek, S. M.; Visco, F.; Zhang, C.; Lokker, N. A.; Lounsbury, D. L.; Robson, M. E.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
    Meeting Abstract

    Traina, T. A.; O'Shaughnessy, J.; Nanda, R.; Schwartzberg, L.; Abramson, V.; Cortes, J.; Peterson, A.; Tudor, I. C.; Blaney, M.; Steinberg, J. L.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer
    Meeting Abstract

    Swain, S. M.; Ewer, M. S.; Douthwaite, H.; Szado, T.; Waldron-Lynch, M.; Dang, C.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc
    Meeting Abstract

    Sikov, W. M.; Barry, W. T.; Hoadley, K. A.; Pitcher, B. N.; Singh, B.; Tolaney, S. M.; Kuzma, C. S.; Pluard, T. J.; Somlo, G.; Port, E. R.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Combination vorinostat and lapatinib reverses epithelial-mesenchymal transition, inhibits the cancer stem cell population of HER2+ breast cancer cells and is effective in heavily pretreated advanced tumors
    Meeting Abstract

    Schech, A. J.; Chumsri, S.; Shah, P.; Yu, S. L.; Tait, N. S.; Bauer, K. S.; Lewis, J. C.; Bao, T.; Edelman, M. J.; Tkaczuk, K. H.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • OlympiA, Neo-Olympia and OlympiAD: Randomized phase III trials of olaparib in patients (pts) with breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)
    Meeting Abstract

    Robson, M.; Tutt, A.; Balmana, J.; Kaufman, B.; Garber, J.; Geyer, C.; Ford, J.; Sharma, P.; Stuart, M.; Mann, H.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save